Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02738151 · ClinicalTrials.gov registry record · Phase 4
Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist
A Phase 4 study of Diabetes Mellitus, Type 2, sponsored by Sanofi.
- Completed
- Registry status
- Phase 4
- Development phase
- 929
- Enrollment target
- 20
- Study locations
NCT02738151 is a Phase 4 study of Diabetes Mellitus, Type 2 that has completed, run by Sanofi. The registered enrollment target is 929 participants, below the 4,483-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT02738151, a Phase 4 study of Diabetes Mellitus, Type 2, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 929 participants
- Enrollment target
- 20
- Study locations
Study Summary
Primary Objective: To demonstrate the noninferiority in the efficacy of Toujeo® to Tresiba® in glycated hemoglobin (HbA1c) change from Baseline to Week 24. Secondary Objectives: Change From Baseline in HbA1c to Week 12 To assess the effects of the insulin Toujeo® in comparison with insulin Tresiba® at week 12 and week 24 on: * Change in Fasting plasma glucose (FPG); * Change in Fasting self-monitored plasma glucose (SMPG) and 4-point SMPG and 8-point SMPG profile; * Percentage of participants reaching HbA1c targets \<7% or ≤6.5%; * Percentage of participants reaching HbA1c targets \<7% or ≤6.5% without severe and/or confirmed hypoglycemia * Frequency of occurrence and diurnal distribution of hypoglycemia by American Diabetes Association (ADA) category of hypoglycemia. To assess the safety in each treatment group. To assess the treatment effects in each treatment group on Patient Reported Outcomes (PRO). Percentage of participants requiring rescue therapy.
Conditions Studied
Interventions
- DRUG Insulin glargine, 300U/mL
- DRUG Insulin degludec, 100 U/mL
- DRUG Non-insulin anti-diabetic treatment
Study Locations (20)
California
- Investigational Site Number 840051 - Anaheim
- Investigational Site Number 840081 - Chino
- Investigational Site Number 840016 - Huntington Park
- Investigational Site Number 840002 - La Jolla
- Investigational Site Number 840091 - Los Angeles
- Investigational Site Number 840058 - Northridge
- Investigational Site Number 840021 - Palm Springs
- Investigational Site Number 840087 - Santa Ana
- Investigational Site Number 840030 - Torrance
- Investigational Site Number 840065 - Van Nuys
Florida
- Investigational Site Number 840075 - Bradenton
- Investigational Site Number 840076 - New Port Richey
- Investigational Site Number 840026 - Ocoee
- Investigational Site Number 840052 - Palm Harbor
- Investigational Site Number 840080 - Palm Harbor
- Investigational Site Number 840018 - Port Charlotte
Georgia
- Investigational Site Number 840071 - Lawrenceville
- Investigational Site Number 840085 - Roswell
Alabama
- Investigational Site Number 840038 - Sheffield
Arizona
- Investigational Site Number 840066 - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 929 participants |
| Start Date | 2016-05-19 |
| Est. Completion | 2017-08-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02738151
The ClinicalTrials.gov registry entry for NCT02738151 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 929 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,483-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (79% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 3 interventions - of which Insulin glargine, 300U/mL is the first listed.
NCT02738151 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT02738151 about?
NCT02738151 is a clinical study titled "Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist". Primary Objective: To demonstrate the noninferiority in the efficacy of Toujeo® to Tresiba® in glycated hemoglobin (HbA1c) change from Baseline to Week 24. Secondary Objectives: Change From Baseline in HbA1c to Week 12 To assess the effects of the insulin Toujeo® in comparison with insulin Tresi...
What is the current status of trial NCT02738151?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 929 participants. The study started on 2016-05-19. Estimated completion is 2017-08-15.
What conditions does trial NCT02738151 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT02738151?
The interventions under investigation include: Insulin glargine, 300U/mL (DRUG), Insulin degludec, 100 U/mL (DRUG), Non-insulin anti-diabetic treatment (DRUG).
Who is sponsoring clinical trial NCT02738151?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02738151 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes
RECRUITING · Phase 4
-
Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes
RECRUITING · Phase 4
-
Effect of Continuing Versus Holding Metformin During Hospitalizations.
RECRUITING · Phase 4
-
Surgical or Medical Treatment
ACTIVE NOT RECRUITING · Phase 4
-
Afrezza® Dosing Optimization Study
COMPLETED · Phase 4
-
Effect of Thiazolidinedione Treatment Vascular Risk Markers
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.